-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
HUTCHMED (China) Limited (NASDAQ:HCM) Sees Large Decline in Short Interest
HUTCHMED (China) Limited (NASDAQ:HCM) Sees Large Decline in Short Interest
HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) was the target of a large decrease in short interest in September. As of September 15th, there was short interest totalling 1,760,000 shares, a decrease of 18.9% from the August 31st total of 2,170,000 shares. Based on an average trading volume of 350,900 shares, the days-to-cover ratio is currently 5.0 days.
HUTCHMED Stock Performance
Shares of HCM traded up $0.23 during mid-day trading on Friday, hitting $8.86. 444,340 shares of the company's stock were exchanged, compared to its average volume of 449,485. The firm has a fifty day moving average of $12.27 and a two-hundred day moving average of $13.25. HUTCHMED has a twelve month low of $8.37 and a twelve month high of $36.81.
Get HUTCHMED alerts:Analyst Ratings Changes
Several research analysts have weighed in on HCM shares. StockNews.com upgraded shares of HUTCHMED from a "sell" rating to a "hold" rating in a research note on Monday, August 1st. The Goldman Sachs Group increased their price target on shares of HUTCHMED from $14.00 to $16.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 9th.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the business. Qube Research & Technologies Ltd acquired a new position in HUTCHMED in the 1st quarter valued at $1,222,000. Capital International Investors grew its stake in HUTCHMED by 1.4% in the 4th quarter. Capital International Investors now owns 9,054,891 shares of the company's stock valued at $317,923,000 after buying an additional 128,422 shares during the last quarter. SG Americas Securities LLC grew its stake in HUTCHMED by 7.2% in the 1st quarter. SG Americas Securities LLC now owns 65,692 shares of the company's stock valued at $1,243,000 after buying an additional 4,406 shares during the last quarter. AIA Group Ltd grew its stake in HUTCHMED by 10.0% in the 1st quarter. AIA Group Ltd now owns 356,640 shares of the company's stock valued at $6,748,000 after buying an additional 32,279 shares during the last quarter. Finally, Baillie Gifford & Co. boosted its holdings in HUTCHMED by 0.5% in the 1st quarter. Baillie Gifford & Co. now owns 365,792 shares of the company's stock valued at $6,921,000 after purchasing an additional 1,724 shares during the period. Institutional investors and hedge funds own 27.37% of the company's stock.HUTCHMED Company Profile
(Get Rating)
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
Recommended Stories
- Get a free copy of the StockNews.com research report on HUTCHMED (HCM)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- Declining Profits Challenge the CarMax Value Proposition
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.
HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) was the target of a large decrease in short interest in September. As of September 15th, there was short interest totalling 1,760,000 shares, a decrease of 18.9% from the August 31st total of 2,170,000 shares. Based on an average trading volume of 350,900 shares, the days-to-cover ratio is currently 5.0 days.
和黃醫藥(中國)有限公司(納斯達克：HCM-GET評級)是空頭股數9月份大幅減持的目標。截至9月15日，空頭股數共有176萬股，比8月31日的217萬股減少了18.9%。以350,900股的平均成交量計算，目前天數與回補比率為5.0天。
HUTCHMED Stock Performance
和黃醫藥股票表現
Shares of HCM traded up $0.23 during mid-day trading on Friday, hitting $8.86. 444,340 shares of the company's stock were exchanged, compared to its average volume of 449,485. The firm has a fifty day moving average of $12.27 and a two-hundred day moving average of $13.25. HUTCHMED has a twelve month low of $8.37 and a twelve month high of $36.81.
在週五午盤交易中，HCM的股價上漲了0.23美元，達到8.86美元。該公司股票成交量為444,340股，而其平均成交量為449,485股。該公司的50日移動均線切入位為12.27美元，200日移動均線切入位為13.25美元。和黃醫藥的12個月低點為8.37美元，12個月高位為36.81美元。
Analyst Ratings Changes
分析師評級發生變化
Several research analysts have weighed in on HCM shares. StockNews.com upgraded shares of HUTCHMED from a "sell" rating to a "hold" rating in a research note on Monday, August 1st. The Goldman Sachs Group increased their price target on shares of HUTCHMED from $14.00 to $16.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 9th.
幾位研究分析師對HCM的股票進行了加碼。在8月1日星期一的一份研究報告中，斯托克新聞網將和黃醫藥的股票評級從賣出上調為持有。8月9日，週二，高盛夫婦將和黃醫藥股票的目標價從14.00美元上調至16.00美元，並在一份研究報告中給予該股“中性”評級。
Institutional Inflows and Outflows
機構資金流入和流出
HUTCHMED Company Profile
和黃醫藥公司簡介
(Get Rating)
(獲取評級)
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
和黃醫藥(中國)有限公司在香港和國際上發現、開發癌症和免疫疾病的靶向療法和免疫療法，並將其商業化。它在腫瘤學/免疫學和其他風險投資領域開展業務。該公司開發Savolitinib，一種治療非小細胞肺癌(NSCLC)、乳頭狀細胞癌和腎癌、結直腸癌(CRC)和胃癌(GC)的抑制劑；以及Fruquintinib，一種治療CRC、乳腺癌、GC、子宮內膜癌(EMC)、非小細胞肺癌、肝細胞癌以及胃腸道和實體腫瘤的抑制劑。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on HUTCHMED (HCM)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- Declining Profits Challenge the CarMax Value Proposition
- 免費獲取斯托克新聞網關於和黃醫藥的研究報告
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat：回顧一週9/26-9/30
- 這是買入美光科技的難忘時刻
- 讓Paychex股票為您努力工作
- 利潤下降對CarMax價值主張的挑戰
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.
接受《和黃醫藥日報》的新聞和評級-在下面輸入您的電子郵件地址，即可通過MarketBeat.com的免費每日電子郵件時事通訊接收對和黃醫藥及相關公司的最新新聞和分析師評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧